Bottom line GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity
By this time next year, we will likely have multiple oral options, a triple agonist that has already been making splashes in the gray market, and a fundamentally different conversation about access
Cagrilintide has progressed through multiple phases of clinical research , with ongoing studies continuing to evaluate its biological activity, pharmacokinetics, and long-term effects
Pathway dysregulation has been observed in the brain, urine and plasma of PD patients, showing a significant reduction of antioxidant enzyme activity along with an increased level of oxidative stress (Rojo et al., 2010) and exacerbation of synuclein aggregation ( Importantly, NRF2 activation has been shown to alleviate PD-associated pathological hallmarks, specifically oxidative stress, mitochondrial dysfunction and neuroinflammation through expression of its target genes (Yang et al., 2022)
Choose between micrograms (mcg), milligrams (mg), or grams (g)
